Naruhito Otani
About
In The Last Decade
Naruhito Otani
32 papers receiving 300 citations
Peers
Comparison fields: 5 of 78
- Epidemiology 99
- Infectious Diseases 82
- Health, Toxicology and Mutagenesis 79
- Pharmacology 59
- Immunology 46
Countries citing papers authored by Naruhito Otani
This map shows the geographic impact of Naruhito Otani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naruhito Otani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naruhito Otani more than expected).
Fields of papers citing papers by Naruhito Otani
This network shows the impact of papers produced by Naruhito Otani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naruhito Otani. The network helps show where Naruhito Otani may publish in the future.
Co-authorship network of co-authors of Naruhito Otani
This figure shows the co-authorship network connecting the top 25 collaborators of Naruhito Otani. A scholar is included among the top collaborators of Naruhito Otani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naruhito Otani. Naruhito Otani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 0 | |
| 3 | 4 | |
| 4 | 16 | |
| 5 | 21 | |
| 6 | 8 | |
| 7 | 4 | |
| 8 | 4 | |
| 9 | 3 | |
| 10 | 24 | |
| 11 | 2 | |
| 12 | 3 | |
| 13 | 12 | |
| 14 | 5 | |
| 15 | 3 | |
| 16 | 42 | |
| 17 | 13 | |
| 18 | 11 | |
| 19 | 23 | |
| 20 | [An autopsied case of interstitial and infectious pneumonia appeared during interferon treatment for C-type chronic active hepatitis]. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.